280 related articles for article (PubMed ID: 16123913)
1. A step change in oral anticoagulation: lack of coagulation monitoring with ximelagatran.
Carlsson SC; Schulman S
Semin Vasc Med; 2005 Aug; 5(3):259-65. PubMed ID: 16123913
[TBL] [Abstract][Full Text] [Related]
2. Effect of melagatran on prothrombin time assays depends on the sensitivity of the thromboplastin and the final dilution of the plasma sample.
Mattsson C; Menschiek-Lundin A; Wåhlander K; Lindahl TL
Thromb Haemost; 2001 Aug; 86(2):611-5. PubMed ID: 11522011
[TBL] [Abstract][Full Text] [Related]
3. Effects of melagatran on activated partial thromboplastin time and on ecarin clotting time in cord versus adult plasma.
Koestenberger M; Gallistl S; Bettina L; Cimenti C; Kutschera J; Cvirn G
Blood Coagul Fibrinolysis; 2006 Nov; 17(8):677-80. PubMed ID: 17102656
[TBL] [Abstract][Full Text] [Related]
4. Anticoagulant action of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, in umbilical cord and adult plasma: an in vitro examination.
Koestenberger M; Gallistl S; Cvirn G; Baier K; Leschnik B; Muntean W
Thromb Res; 2005; 115(1-2):135-42. PubMed ID: 15567465
[TBL] [Abstract][Full Text] [Related]
5. Low potential for interactions between melagatran/ximelagatran and other drugs, food, or alcohol.
Wolzt M; Sarich TS; Eriksson UG
Semin Vasc Med; 2005 Aug; 5(3):254-8. PubMed ID: 16123912
[TBL] [Abstract][Full Text] [Related]
6. Differences in the clinically effective molar concentrations of four direct thrombin inhibitors explain their variable prothrombin time prolongation.
Warkentin TE; Greinacher A; Craven S; Dewar L; Sheppard JA; Ofosu FA
Thromb Haemost; 2005 Nov; 94(5):958-64. PubMed ID: 16363236
[TBL] [Abstract][Full Text] [Related]
7. Differential effects of TAK-442, a novel orally active direct factor Xa inhibitor, and ximelagatran, a thrombin inhibitor, on factor V-mediated feedback on coagulation cascade and bleeding.
Konishi N; Hiroe K; Kawamura M
Thromb Haemost; 2010 Sep; 104(3):504-13. PubMed ID: 20664909
[TBL] [Abstract][Full Text] [Related]
8. Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate.
Douxfils J; Mullier F; Robert S; Chatelain C; Chatelain B; Dogné JM
Thromb Haemost; 2012 May; 107(5):985-97. PubMed ID: 22438031
[TBL] [Abstract][Full Text] [Related]
9. Standardization of coagulation tests.
Opartkiattikul N
Southeast Asian J Trop Med Public Health; 1999; 30 Suppl 3():79-85. PubMed ID: 10926265
[TBL] [Abstract][Full Text] [Related]
10. No influence of mild-to-moderate hepatic impairment on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor.
Wåhlander K; Eriksson-Lepkowska M; Frison L; Fager G; Eriksson UG
Clin Pharmacokinet; 2003; 42(8):755-64. PubMed ID: 12846596
[TBL] [Abstract][Full Text] [Related]
11. The respective and combined anticoagulant effects of recombinant human activated protein C, melagatran and heparins using CAT.
Cimenti C; Koestenberger M; Leschnik B; Haidl H; Muntean W
Thromb Res; 2007; 119(3):361-7. PubMed ID: 16712904
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and pharmacodynamics of ximelagatran.
Wolzt M; Sarich TS; Eriksson UG
Semin Vasc Med; 2005 Aug; 5(3):245-53. PubMed ID: 16123911
[TBL] [Abstract][Full Text] [Related]
13. Orally active direct thrombin inhibitors.
Weitz J
Semin Vasc Med; 2003 May; 3(2):131-8. PubMed ID: 15199476
[TBL] [Abstract][Full Text] [Related]
14. Ximelagatran for the prevention of venous thromboembolism following elective hip or knee replacement surgery.
Colwell C; Mouret P
Semin Vasc Med; 2005 Aug; 5(3):266-75. PubMed ID: 16123914
[TBL] [Abstract][Full Text] [Related]
15. Effects of melagatran, a new low-molecular-weight thrombin inhibitor, on thrombin and fibrinolytic enzymes.
Gustafsson D; Antonsson T; Bylund R; Eriksson U; Gyzander E; Nilsson I; Elg M; Mattsson C; Deinum J; Pehrsson S; Karlsson O; Nilsson A; Sörensen H
Thromb Haemost; 1998 Jan; 79(1):110-8. PubMed ID: 9459334
[TBL] [Abstract][Full Text] [Related]
16. Biochemical and pharmacological effects of the direct thrombin inhibitor AR-H067637.
Deinum J; Mattsson C; Inghardt T; Elg M
Thromb Haemost; 2009 Jun; 101(6):1051-9. PubMed ID: 19492147
[TBL] [Abstract][Full Text] [Related]
17. Vitamin K deficiency amplifies anticoagulation response to ximelagatran: possible implications for direct thrombin inhibitors and their clinical safety.
Kamali F; Wood P; Ward A
Ann Hematol; 2009 Feb; 88(2):141-9. PubMed ID: 18716776
[TBL] [Abstract][Full Text] [Related]
18. Assessment of laboratory assays to measure rivaroxaban--an oral, direct factor Xa inhibitor.
Samama MM; Martinoli JL; LeFlem L; Guinet C; Plu-Bureau G; Depasse F; Perzborn E
Thromb Haemost; 2010 Apr; 103(4):815-25. PubMed ID: 20135059
[TBL] [Abstract][Full Text] [Related]
19. Influence of severe renal impairment on the pharmacokinetics and pharmacodynamics of oral ximelagatran and subcutaneous melagatran.
Eriksson UG; Johansson S; Attman PO; Mulec H; Frison L; Fager G; Samuelsson O
Clin Pharmacokinet; 2003; 42(8):743-53. PubMed ID: 12846595
[TBL] [Abstract][Full Text] [Related]
20. Additive effects of anticoagulants: recombinant human activated protein C and heparin or melagatran, in tissue factor-activated umbilical-cord plasma.
Koestenberger M; Gallistl S; Muntean W; Leschnik B; Fritsch P; Cvirn G
Thromb Haemost; 2005 Jul; 94(1):69-74. PubMed ID: 16113786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
